通过其发展和结构洞察来解释c-Jun N-终端激酶3 (JNK3) 抑制剂的异形选择性
Haoqing Yu1, Xiangyu Zhang2, Zhenming Liu1,3
1State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Journal of medicinal chemistry
|December 12, 2025
概括
c-Jun N-终端酶3 (JNK3) 在神经退行性疾病中至关重要. 开发选择性JNK3抑制剂具有挑战性,但对于治疗进步至关重要,需要创新的结构和设计策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 结构生物学 结构生物学
背景情况:
- c-Jun N-终端激酶3 (JNK3),一种大脑丰富的基因激活蛋白激酶 (MAPK),与神经退行性疾病,玻璃眼,ALS和癌症有关.
- 在疾病发病过程中JNK3的作用使其成为一种重要的药物标.
- 目前的JNK3抑制剂的有限的异型选择性阻碍了治疗的发展.
研究的目的:
- 阐明JNK3调节的途径及其独特的功能.
- 为JNK3连接体相互作用提供结构基础.
- 根据化学支架分析和分类JNK3抑制剂,并讨论异型选择性.
主要方法:
- 详细的JNK3复合物的结构分析与各种连接体.
- 基于其化学支架的抑制剂的系统分类.
- 探索分子结合相互作用和抑制剂设计的结构逻辑.
主要成果:
- 确定控制JNK3结合的关键分子相互作用.
- 对JNK3抑制剂的分类揭示了结构-活性关系.
- 了解JNK3抑制剂设计中异形选择性的结构基础.
结论:
- 设计JNK3抑制剂需要对结构和结合性质有深入的了解.
- 克服异形选择性挑战对于有效的JNK3向疗法至关重要.
- 需要创新策略来推进选择性JNK3抑制剂的发现.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.7K
13:22Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
8.2K
相关概念视频
The JAK-STAT Signaling Pathway
11.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.7K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
cAMP-dependent Protein Kinase Pathways
8.2K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.2K
MAPK Signaling Cascades
7.8K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.8K
PI3K/mTOR/AKT Signaling Pathway
5.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.2K
Protein Kinases and Phosphatases
4.3K
4.3K
